Comparative in vitro studies on cefotaxime and desacetylcefotaxime

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Cefotaxime is partially metabolized to desacetylcefotaxime in vivo.
• Understanding the activity of cefotaxime and its metabolite is crucial for optimizing antibiotic therapy.

Purpose of the Study:

• To compare the in vitro antibacterial activity and beta-lactamase stability of cefotaxime and desacetylcefotaxime.
• To evaluate the synergistic potential of cefotaxime and desacetylcefotaxime combinations.

Main Methods:

• In vitro testing of bacteriostatic and bactericidal activity against clinical isolates.
• Beta-lactamase stability assays.
• Checkerboard and killing curve methods for combination studies.

Main Results:

• Cefotaxime demonstrated 4-8 times greater activity than desacetylcefotaxime against most strains, with smaller differences against specific Enterobacteriaceae, Haemophilus influenzae, and gonococci.
• Cefotaxime exhibited superior beta-lactamase stability compared to its desacetyl derivative.
• Cefotaxime was generally the most active beta-lactam agent, comparable in efficacy to gentamicin, netilmicin, and ciprofloxacin, except against pseudomonads, staphylococci, and enterococci.
• Synergy was observed between cefotaxime and desacetylcefotaxime against most tested organisms.

Conclusions:

• Cefotaxime is more potent than its desacetyl metabolite, but the metabolite retains some activity.
• The combination of cefotaxime and desacetylcefotaxime exhibits synergy, which may enhance cefotaxime's in vivo efficacy.
• These findings support the continued use of cefotaxime in clinical practice, even with its partial metabolism.